Vistagen Therapeutics (VTGN) Retained Earnings (2016 - 2025)
Vistagen Therapeutics (VTGN) has disclosed Retained Earnings for 13 consecutive years, with -$461.0 million as the latest value for Q4 2025.
- Quarterly Retained Earnings fell 17.02% to -$461.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$461.0 million through Dec 2025, down 17.02% year-over-year, with the annual reading at -$407.6 million for FY2025, 14.43% down from the prior year.
- Retained Earnings hit -$461.0 million in Q4 2025 for Vistagen Therapeutics, down from $14000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $22000.0 in Q3 2024 to a low of -$461.0 million in Q4 2025.
- Historically, Retained Earnings has averaged -$272.3 million across 5 years, with a median of -$309.7 million in 2022.
- Biggest five-year swings in Retained Earnings: surged 100.01% in 2024 and later tumbled 36.36% in 2025.
- Year by year, Retained Earnings stood at -$250.9 million in 2021, then dropped by 25.39% to -$314.6 million in 2022, then decreased by 10.19% to -$346.7 million in 2023, then decreased by 13.65% to -$394.0 million in 2024, then dropped by 17.02% to -$461.0 million in 2025.
- Business Quant data shows Retained Earnings for VTGN at -$461.0 million in Q4 2025, $14000.0 in Q3 2025, and $1000.0 in Q2 2025.